BRPI0911577A2 - derivados espiro-indol para o tratamento de doenças parasíticas. - Google Patents

derivados espiro-indol para o tratamento de doenças parasíticas.

Info

Publication number
BRPI0911577A2
BRPI0911577A2 BRPI0911577A BRPI0911577A BRPI0911577A2 BR PI0911577 A2 BRPI0911577 A2 BR PI0911577A2 BR PI0911577 A BRPI0911577 A BR PI0911577A BR PI0911577 A BRPI0911577 A BR PI0911577A BR PI0911577 A2 BRPI0911577 A2 BR PI0911577A2
Authority
BR
Brazil
Prior art keywords
treatment
parasitic diseases
spiroindole
derivatives
spiroindole derivatives
Prior art date
Application number
BRPI0911577A
Other languages
English (en)
Inventor
Bin Zou
Bryan Ks Yeung
Liying Jocelyn Tan
Philipp Krastel
Seh Yong Leong
Shi Hua Ang
Wen Lin Josephine Wong
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40613087&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0911577(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BRPI0911577A2 publication Critical patent/BRPI0911577A2/pt
Publication of BRPI0911577A8 publication Critical patent/BRPI0911577A8/pt
Publication of BRPI0911577B1 publication Critical patent/BRPI0911577B1/pt
Publication of BRPI0911577B8 publication Critical patent/BRPI0911577B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/20—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
BRPI0911577A 2008-04-29 2009-04-01 derivados espiro-indol, seus usos no tratamento de doenças parasíticas, e composição farmacêutica BRPI0911577B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP08155342.2 2008-04-29
EP08155342 2008-04-29
EP09151117.0 2009-01-22
EP09151117 2009-01-22
PCT/EP2009/053902 WO2009132921A1 (en) 2008-04-29 2009-04-01 Spiro-indole derivatives for the treatment of parasitic diseases

Publications (4)

Publication Number Publication Date
BRPI0911577A2 true BRPI0911577A2 (pt) 2016-01-05
BRPI0911577A8 BRPI0911577A8 (pt) 2018-03-06
BRPI0911577B1 BRPI0911577B1 (pt) 2021-02-23
BRPI0911577B8 BRPI0911577B8 (pt) 2021-05-25

Family

ID=40613087

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0911577A BRPI0911577B8 (pt) 2008-04-29 2009-04-01 derivados espiro-indol, seus usos no tratamento de doenças parasíticas, e composição farmacêutica

Country Status (31)

Country Link
US (2) US8053442B2 (pt)
EP (2) EP2285808B1 (pt)
JP (2) JP5438098B2 (pt)
KR (1) KR101390081B1 (pt)
CN (1) CN102015711B (pt)
AR (1) AR071222A1 (pt)
AU (1) AU2009242279B2 (pt)
BR (1) BRPI0911577B8 (pt)
CA (1) CA2719365C (pt)
CL (1) CL2009001007A1 (pt)
CO (1) CO6300940A2 (pt)
CY (1) CY1114874T1 (pt)
DK (1) DK2285808T3 (pt)
EA (1) EA019601B1 (pt)
EC (2) ECSP10010646A (pt)
ES (1) ES2447590T3 (pt)
HK (1) HK1149935A1 (pt)
HR (1) HRP20140151T1 (pt)
IL (1) IL208357A (pt)
JO (1) JO2904B1 (pt)
MA (1) MA32316B1 (pt)
MX (1) MX2010011868A (pt)
MY (2) MY156601A (pt)
NZ (1) NZ588217A (pt)
PE (1) PE20091787A1 (pt)
PL (1) PL2285808T3 (pt)
PT (1) PT2285808E (pt)
SI (1) SI2285808T1 (pt)
TW (1) TWI442921B (pt)
WO (1) WO2009132921A1 (pt)
ZA (1) ZA201006752B (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2285808T3 (pl) * 2008-04-29 2014-04-30 Novartis Ag Spiro-indolowe pochodne do leczenia chorób pasożytniczych
CN102584835B (zh) * 2011-01-17 2014-08-27 苏州大学 一种含吲哚结构的螺杂环化合物及其制备方法
HUE046421T2 (hu) 2012-03-23 2020-02-28 Novartis Ag Kémiai eljárás spiroindolok és intermedierjeik elõállítására
CN104185634B (zh) * 2012-03-23 2017-05-03 诺华股份有限公司 制备螺旋吲哚酮和其中间体的化学工艺
DK2828385T3 (en) 2012-03-23 2018-03-12 Codexis Inc BIOCATALIZATORS AND METHODS FOR SYNTHETIZING DERIVATIVES AND TRYPTAMIN AND TRYPTAMINE ANALOGS
DK3068793T3 (da) 2013-11-13 2021-03-22 Codexis Inc Manipulerede iminreductaser og fremgangsmåder til den reduktive aminering af keton- og aminforbindelser
CA2968275C (en) 2014-11-25 2023-09-12 Codexis, Inc. Engineered imine reductases and methods for the reductive amination of ketone and amine compounds
JP6679147B2 (ja) 2014-12-18 2020-04-15 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト テトラヒドロ−ピリド［３，４−ｂ］インドールエストロゲン受容体モジュレーター及びその使用
SG11201705626QA (en) * 2015-01-23 2017-08-30 Glaxosmithkline Ip Dev Ltd Pyrazolo[3,4-d]pyrimidin derivative and its use for the treatment of leishmaniasis
WO2016147205A1 (en) * 2015-03-13 2016-09-22 Council Of Scientific & Industrial Research Novel substituted 3-spirophosphoryl pyrazole-2-oxindoles as anti-infectives and process for the synthesis thereof
WO2016201440A1 (en) * 2015-06-12 2016-12-15 The Regents Of The University Of California Spiroindolinones and therapeutic uses thereof
JP2017024992A (ja) * 2015-07-15 2017-02-02 公益財団法人微生物化学研究会 化合物の製造方法
MX2020011531A (es) 2018-06-21 2021-03-25 Hoffmann La Roche Formas sólidas de 3-((1r,3r)-1-(2,6-difluoro-4-((1-(3-fluoropropil )azetidin-3 il)amino)fenil)-3-metil-1,3,4,9-tetrahidro-2h-pirido[3 ,4-b]indol-2-il)-2,2 difluoropropan-1-ol y procesos para preparar compuestos tricíclicos fusionados que comprenden un resto fenilo o piridinilo sustituido, incluidos métodos para su uso.
CN110590795B (zh) * 2019-10-10 2021-01-22 贵州省中国科学院天然产物化学重点实验室(贵州医科大学天然产物化学重点实验室) 一类多并杂环螺羟吲哚类化合物的合成方法
US20230132973A1 (en) * 2020-03-17 2023-05-04 The University Of Buea DIHYDRO-SPIRO[INDOLINE-3:1'-iSOQUINOLIN]-2-ONES AS ANTIMALARIAL AGENTS
CN116273188B (zh) * 2023-03-01 2024-06-25 岭南师范学院 一种负载金属的多孔有机框架材料在催化Pictet-Spengler反应中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2663935A1 (fr) * 1990-06-27 1992-01-03 Adir Nouveaux 1,2,3,4,5,6-hexahydroazepino [4,5-b] indoles et 1,2,3,4-tetrahydrobethacarbolines, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent.
US6984640B1 (en) * 1998-07-14 2006-01-10 Bayer Aktiengesellschaft Antiparasitic artemisinin derivatives (endoperoxides)
ID29268A (id) 1998-12-19 2001-08-16 Janssen Pharmaceutica Nv Senyawa spiro yang bersifat antihistamin
US20050137220A1 (en) 2003-07-23 2005-06-23 Pharmacia Corporation Beta-carboline compounds and analogues thereof as mitogen-activated protein kinase-activated protein kinase-2 inhibitors
AR053710A1 (es) 2005-04-11 2007-05-16 Xenon Pharmaceuticals Inc Compuestos espiroheterociclicos y sus usos como agentes terapeuticos
MX2009005504A (es) 2006-12-07 2009-06-03 Hoffmann La Roche Derivados de espiro piperidina como antagonistas del receptor via.
EP2219646A4 (en) * 2007-12-21 2010-12-22 Univ Rochester METHOD FOR MODIFYING THE LIFETIME OF EUKARYOTIC ORGANISMS
CN102015708B (zh) 2008-01-09 2014-03-26 阵列生物制药公司 作为akt蛋白激酶抑制剂的嘧啶基环戊烷
PL2285808T3 (pl) * 2008-04-29 2014-04-30 Novartis Ag Spiro-indolowe pochodne do leczenia chorób pasożytniczych

Also Published As

Publication number Publication date
AU2009242279B2 (en) 2012-08-30
ECSP10010646A (es) 2010-12-30
CY1114874T1 (el) 2016-12-14
US20110275613A1 (en) 2011-11-10
ZA201006752B (en) 2011-05-25
KR101390081B1 (ko) 2014-04-29
CN102015711A (zh) 2011-04-13
WO2009132921A1 (en) 2009-11-05
IL208357A0 (en) 2010-12-30
EP2722333A1 (en) 2014-04-23
CA2719365A1 (en) 2009-11-05
MA32316B1 (fr) 2011-05-02
HRP20140151T1 (hr) 2014-03-28
MY156601A (en) 2016-03-15
CL2009001007A1 (es) 2010-06-11
JP2011518852A (ja) 2011-06-30
EA201001689A1 (ru) 2011-08-30
NZ588217A (en) 2012-10-26
CN102015711B (zh) 2013-05-01
JO2904B1 (en) 2015-09-15
EP2285808A1 (en) 2011-02-23
US8053442B2 (en) 2011-11-08
JP2014065729A (ja) 2014-04-17
PT2285808E (pt) 2014-02-24
CA2719365C (en) 2017-03-07
AU2009242279A1 (en) 2009-11-05
BRPI0911577B1 (pt) 2021-02-23
DK2285808T3 (da) 2014-02-03
US20090275560A1 (en) 2009-11-05
TW200948357A (en) 2009-12-01
MX2010011868A (es) 2010-11-26
IL208357A (en) 2014-11-30
KR20100135320A (ko) 2010-12-24
BRPI0911577A8 (pt) 2018-03-06
TWI442921B (zh) 2014-07-01
ES2447590T3 (es) 2014-03-12
JP5438098B2 (ja) 2014-03-12
BRPI0911577B8 (pt) 2021-05-25
MY152021A (en) 2014-08-15
PL2285808T3 (pl) 2014-04-30
EA019601B1 (ru) 2014-04-30
AR071222A1 (es) 2010-06-02
ECSP17068127A (es) 2017-10-31
SI2285808T1 (sl) 2014-03-31
CO6300940A2 (es) 2011-07-21
US8399453B2 (en) 2013-03-19
HK1149935A1 (en) 2011-10-21
EP2285808B1 (en) 2013-11-20
PE20091787A1 (es) 2009-12-14

Similar Documents

Publication Publication Date Title
BRPI0911577A8 (pt) derivados espiro-indol para o tratamento de doenças parasíticas.
LTPA2020510I1 (lt) Pakeistieji 4-fenil-piridinai, skirti su NK-receptoriumi susijusių ligų gydymui
SMP200900085B (it) 3-imidazolil-indoli per il trattamento di malattieproliferative.
BRPI0908026A2 (pt) Métodos para o tratamento de doenças do intestino
BRPI1015569A2 (pt) compostos úteis para o tratamento de doenças degenerativas e inflamatórias.
BRPI0716844A2 (pt) Inidores de quinase úteis para o tratamento de doenças proliferativas
DK2504005T3 (da) Anvendelse af 1,3-diphenylprop-2-en-1-on-derivater til behandling af lever-sygdomme
BRPI0918476A2 (pt) dímeros de pirrolobenzodiazepina assimétricos para o tratamento de doenças proliferativas
DK3456707T3 (da) 4-(p-quinonyl)-2-hydroxybutanamidderivater til behandling af mitokondriesygdomme
BRPI0807987A2 (pt) Terapia de combinação para tratamento de distúrbios imunes.
BRPI0919920A2 (pt) compostos para tratamento de doenças e desordens oftálmicas
BRPI0816784A2 (pt) Fatores neuro-endócrinos para o tratamento de doenças degenerativas
BRPI1012116A2 (pt) composição farmacêutica para o tratamento de doenças cardíacas
DK2056842T3 (da) Modificeret galactosylceramid til behandling af cancerøse sygdomme
BRPI1009783A2 (pt) compostos para o tratamento de distúrbios metabólicos.
BRPI1007995A2 (pt) orto-aminoamidas para o tratamento de cãncer.
IT1391866B1 (it) Composizione iniettabile di polinucleotidi per il trattamento di patologie osteoarticolari.
BR112012004836A2 (pt) pirazinilpiridinas úteis para o tratamento de doenças proliferativas
BRPI0815551A2 (pt) Tratamento através de hucbc de doença beta-amiloide
DK1993589T3 (da) Behandlinger for neurologiske sygdomme
BRPI0816712A2 (pt) terapia de intervalo para o tratamento de tinnitus
BRPI0818170A2 (pt) 5-cianotienopiridinas para o tratamento de tumores.
BRPI0906606A2 (pt) Tratamento terapêutico para condições do pulmão.
DK2117565T3 (da) Anvendelse af chitosaner til behandlingen af negleinflammatoriske sygdomme
ITRM20050179A1 (it) Composizione impiegabile per il trattamento delle patologie paradontali.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 23/02/2021, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 01/04/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF